A global multicenter study, CHECKMATE-649 (CM649), found that the efficacy of chemotherapy combined with immunotherapy as a first-line treatment regimen for patients with human epidermal growth factor receptor 2-negative (HER-2−) advanced GC was superior to that of standard chemotherapy [3]. Here, ERBB2 is linked to gastric cancer.